laboratory Coagulation Tests
Intro
Don't forget to go to Practical Haemostasis for the real deal. In addition, BSH produced a guideline in 2020 on laboratory aspects used in haemostasis and thrombosis which covers specifics of setting up coag assays within the lab in detail (Ref ranges, cut-off values, calibration & the assays available for different tests).
Preanalytical Variables:
Patient identification
Sampling technique – needle gauge, patient stress
Sample volume & tube used
Haemolysis, Icterus and Lipaemia (‘HIL’) or presence of anticoagulants in sample
Transport – temperature, agitation, delays reaching lab
Correcting for presence of anticoagulants:
Commercial products available to remove or correct for anticoagulant medications
e.g. Hepzyme to neutralise heparin effects
e.g. DOAC-Stop, DOAC-Remove or Activated charcoal to counter direct oral anticoagulants
Basics
Prothrombin Time
1. PPP + (Tissue Factor + Phospholipid) at 37oC
2. Add calcium and time to clot
International Normalised Ratio
(Patient PT / Reference PT) to the power of ISI
Or can be expressed as (PT Ratio) to the power of ISI
Activated Partial Thromboplastin Time
1. PPP + Activator + Phospholipid at 37oC
2. Add calcium and time to clot
(Activators – Kaolin, Silica)
Thrombin Time
1. PPP + Thrombin at 37oC
2. Time to clot
(Thombin – human or bovine source)
Clauss Fibrinogen
1. Dilute PPP + Excess of Thrombin + Phospholipid at 37oC
2. Add calcium and time to clot
3. Compare time to calibration curves of reference plasma
Drug Monitoring
Haemoclot Thrombin Time
1. Dilute PPP + Normal Plasma + Thrombin at 37oC
2. Time to clot
Time is proportional to plasma concentration of DTI
Reptilase Time
1. PPP + Reptilase at 37oC
2. Time to clot
Reptilase cleaves fibrinopeptide A to fibrin. Like TT but not prolonged by LMWH/VKA/DTI
Ecarin Clotting Time
1. Dilute PPP + Ecarin
2. Time to clot
Ecarin generates meizothrombin. This then has to be cleaved to thrombin, which is the rate limiting step to clot formation. ECT is prolong by DTIs, but unaffected by Heparins
Activated Clotting Time
1. Immediate use of whole blood + Surface Activator
2. Time to clot
Used for POC monitoring of UFH in bypass/ECMO
Chromogenic Anti-Xa Assay
1. Commercial plasms with known LMWH concentration + known amount of Xa
2. PPP + Known amount of Xa
3. Heparin binds to Antithrombin, binds to Xa —> Hep-AT-Xa complex
4. Residual Xa measured by chromogenic assay using a Xa-specific substrate
Result, ie residual Xa activity, is inversely proportional to the amount of heparin in sample
Result is compared to a reference curve constructed using dilutions of the relevant heparin
Factor Assays
1-Stage PT-based Assay
1. PPP + Commercial factor deficient plasma
2. Use this mix to perform PT
3. Compare result to control plasma dilutions
1-Stage APTT-based Assay
As for 1-Stage PT but with alternative reagents.
Certain F8 gene mutations, and recombinant FVIII concentrates, can cause discrepant results between 1-stage vs 2-stage/chromogenic assays.
Typically results in 2x higher FVIII:C with the 1-stage compared to 2-stage/chromogenic
In these situations, the 1-stage may give a result within the normal range
But the discrepancy can be the other way round
The bleeding phenotype usually correlates best with the 2-stage/chromogenic assay
2-Stage Factor VIII Assay
1. Adsorb patient’s PPP to remove II, VII, IX and X
2. Mix with activated serum (IX, X, XIa) + V + Phospholipid + Calcium
3. Incuate at 37oC to produce Xa (patient’s FVIII level is the rate limiting step)
4. Now mix 1st stage product with normal plasma and perform APTT
5. Time to clot is proportional to the Xa that was produced in the 1st stage, which is turn was proportional to the FVIII:C in the patient sample.
Chromogenic Factor VIII Assay
1. PPP + Reagent Cocktail (IXa, X, Thrombin, Phospholipid, Calcium)
2. Incubate at 37oC to produce Xa
3. Add chromogenic substrate and incubate
4. Colour change occurs on cleavage of substrate by Xa —> Calculate Xa concentration
As with 2-stage APTT assay, the patient’s FVIII level is the limiting step in Xa production
Glossary
PPP – Platelet Poor Plasma
DTI – Direct Thrombin Inhibitors
VKA – Vitamin K antagonists
POC – Point of care
UFH – Unfractionated heparin